Treatment of myeloid malignancies relapsing after allogeneic hematopoietic stem cell transplantation with venetoclax and hypomethylating agents—a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group

  1. Schuler, Esther ORCID logo
  2. Wagner-Drouet, Eva-Maria
  3. Ajib, Salem
  4. Bug, Gesine
  5. Crysandt, Martina
  6. Dressler, Sabine
  7. Hausmann, Andreas
  8. Heidenreich, Daniela
  9. Hirschbühl, Klaus
  10. Hoepting, Matthias
  11. Jost, Edgar
  12. Kaivers, Jennifer
  13. Klein, Stefan
  14. Koldehoff, Michael
  15. Kordelas, Lambros
  16. Kriege, Oliver
  17. Müller, Lutz P.
  18. Rautenberg, Christina
  19. Schaffrath, Judith
  20. Schmid, Christoph
  21. Wolff, Daniel
  22. Haas, Rainer
  23. Bornhäuser, Martin
  24. Schroeder, Thomas
  25. Kobbe, Guido

Download
s00277-020-04321-x.pdf 406,99KB
WeightNameValue
1000 Titel
  • Treatment of myeloid malignancies relapsing after allogeneic hematopoietic stem cell transplantation with venetoclax and hypomethylating agents—a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group
1000 Autor/in
  1. Schuler, Esther |
  2. Wagner-Drouet, Eva-Maria |
  3. Ajib, Salem |
  4. Bug, Gesine |
  5. Crysandt, Martina |
  6. Dressler, Sabine |
  7. Hausmann, Andreas |
  8. Heidenreich, Daniela |
  9. Hirschbühl, Klaus |
  10. Hoepting, Matthias |
  11. Jost, Edgar |
  12. Kaivers, Jennifer |
  13. Klein, Stefan |
  14. Koldehoff, Michael |
  15. Kordelas, Lambros |
  16. Kriege, Oliver |
  17. Müller, Lutz P. |
  18. Rautenberg, Christina |
  19. Schaffrath, Judith |
  20. Schmid, Christoph |
  21. Wolff, Daniel |
  22. Haas, Rainer |
  23. Bornhäuser, Martin |
  24. Schroeder, Thomas |
  25. Kobbe, Guido |
1000 Erscheinungsjahr 2020
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2020-11-16
1000 Erschienen in
1000 Quellenangabe
  • 100(4):959-968
1000 Copyrightjahr
  • 2020
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1007/s00277-020-04321-x |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8448702/ |
1000 Publikationsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • Treatment of relapse after allogeneic hematopoietic stem cell transplantation (alloHSCT) remains a great challenge. Aiming to evaluate the combination of venetoclax and hypomethylating agents (HMAClax) for the treatment of relapse of myeloid malignancies after alloHSCT, we retrospectively collected data from 32 patients treated at 11 German centers. Venetoclax was applied with azacitidine (n = 13) or decitabine (n = 19); 11 patients received DLI in addition. HMAClax was the first salvage therapy in 8 patients. The median number of cycles per patient was 2 (1-19). All but 1 patient had grade 3/4 neutropenia. Hospital admission for grade 3/4 infections was necessary in 23 patients (72%); 5 of these were fatal. In 30 evaluable patients, overall response rate (ORR) was 47% (14/30, 3 CR MRD
1000 Sacherschließung
lokal Allografts [MeSH]
lokal Bridged Bicyclo Compounds, Heterocyclic/administration
lokal DNA Methylation/drug effects [MeSH]
lokal DLI
lokal Febrile Neutropenia/chemically induced [MeSH]
lokal Myelodysplastic Syndromes/therapy [MeSH]
lokal Azacitidine/administration
lokal Salvage Therapy/adverse effects [MeSH]
lokal Leukocyte Count [MeSH]
lokal Germany/epidemiology [MeSH]
lokal Febrile Neutropenia/blood [MeSH]
lokal Sulfonamides/adverse effects [MeSH]
lokal Original Article
lokal Decitabine
lokal Decitabine/pharmacology [MeSH]
lokal Myelodysplastic Syndromes/drug therapy [MeSH]
lokal Venetoclax
lokal Thrombocytopenia/chemically induced [MeSH]
lokal Combined Modality Therapy [MeSH]
lokal Leukemia, Myeloid, Acute/therapy [MeSH]
lokal Relapse
lokal Thrombocytopenia/blood [MeSH]
lokal Bridged Bicyclo Compounds, Heterocyclic/adverse effects [MeSH]
lokal Transplantation Conditioning [MeSH]
lokal Drug Evaluation [MeSH]
lokal Hypomethylating agents
lokal Kaplan-Meier Estimate [MeSH]
lokal Humans [MeSH]
lokal Azacitidine/pharmacology [MeSH]
lokal Hematopoietic Stem Cell Transplantation [MeSH]
lokal Retrospective Studies [MeSH]
lokal Allogeneic hematopoietic stem cell transplantation
lokal Sulfonamides/administration
lokal Antineoplastic Combined Chemotherapy Protocols/therapeutic use [MeSH]
lokal Recurrence [MeSH]
lokal Antineoplastic Combined Chemotherapy Protocols/adverse effects [MeSH]
lokal Azacitidine
lokal Azacitidine/adverse effects [MeSH]
lokal Decitabine/administration
lokal Immunosuppressive Agents/therapeutic use [MeSH]
lokal Leukemia, Myeloid, Acute/drug therapy [MeSH]
lokal Tumor Lysis Syndrome/etiology [MeSH]
lokal Immunosuppressive Agents/adverse effects [MeSH]
lokal Decitabine/adverse effects [MeSH]
1000 Liste der Beteiligten
  1. https://orcid.org/0000-0001-7182-6502|https://frl.publisso.de/adhoc/uri/V2FnbmVyLURyb3VldCwgRXZhLU1hcmlh|https://frl.publisso.de/adhoc/uri/QWppYiwgU2FsZW0=|https://frl.publisso.de/adhoc/uri/QnVnLCBHZXNpbmU=|https://frl.publisso.de/adhoc/uri/Q3J5c2FuZHQsIE1hcnRpbmE=|https://frl.publisso.de/adhoc/uri/RHJlc3NsZXIsIFNhYmluZQ==|https://frl.publisso.de/adhoc/uri/SGF1c21hbm4sIEFuZHJlYXM=|https://frl.publisso.de/adhoc/uri/SGVpZGVucmVpY2gsIERhbmllbGE=|https://frl.publisso.de/adhoc/uri/SGlyc2NoYsO8aGwsIEtsYXVz|https://frl.publisso.de/adhoc/uri/SG9lcHRpbmcsIE1hdHRoaWFz|https://frl.publisso.de/adhoc/uri/Sm9zdCwgRWRnYXI=|https://frl.publisso.de/adhoc/uri/S2FpdmVycywgSmVubmlmZXI=|https://frl.publisso.de/adhoc/uri/S2xlaW4sIFN0ZWZhbg==|https://frl.publisso.de/adhoc/uri/S29sZGVob2ZmLCBNaWNoYWVs|https://frl.publisso.de/adhoc/uri/S29yZGVsYXMsIExhbWJyb3M=|https://frl.publisso.de/adhoc/uri/S3JpZWdlLCBPbGl2ZXI=|https://frl.publisso.de/adhoc/uri/TcO8bGxlciwgTHV0eiBQLg==|https://frl.publisso.de/adhoc/uri/UmF1dGVuYmVyZywgQ2hyaXN0aW5h|https://frl.publisso.de/adhoc/uri/U2NoYWZmcmF0aCwgSnVkaXRo|https://frl.publisso.de/adhoc/uri/U2NobWlkLCBDaHJpc3RvcGg=|https://frl.publisso.de/adhoc/uri/V29sZmYsIERhbmllbA==|https://frl.publisso.de/adhoc/uri/SGFhcywgUmFpbmVy|https://frl.publisso.de/adhoc/uri/Qm9ybmjDpHVzZXIsIE1hcnRpbg==|https://frl.publisso.de/adhoc/uri/U2Nocm9lZGVyLCBUaG9tYXM=|https://frl.publisso.de/adhoc/uri/S29iYmUsIEd1aWRv
1000 Hinweis
  • DeepGreen-ID: 864b8830864e433895dcdc6b41ce5abb ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Dateien
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6467026.rdf
1000 Erstellt am 2023-11-17T05:44:03.121+0100
1000 Erstellt von 322
1000 beschreibt frl:6467026
1000 Zuletzt bearbeitet 2023-12-01T05:20:56.927+0100
1000 Objekt bearb. Fri Dec 01 05:20:56 CET 2023
1000 Vgl. frl:6467026
1000 Oai Id
  1. oai:frl.publisso.de:frl:6467026 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source